Diagnosis and Clinical Development of Sporadic Inclusion Body Myositis and Polymyositis With Mitochondrial Pathology: A Single-Center Retrospective Analysis
Open Access
- 13 October 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Neuropathology and Experimental Neurology
- Vol. 80 (11), 1060-1067
- https://doi.org/10.1093/jnen/nlab101
Abstract
To review our diagnostic and treatment approaches concerning sporadic inclusion body myositis (sIBM) and polymyositis with mitochondrial pathology (PM-Mito), we conducted a retrospective analysis of clinical and histological data of 32 patients diagnosed as sIBM and 7 patients diagnosed as PM-Mito by muscle biopsy. Of 32 patients identified histologically as sIBM, 19 fulfilled the 2011 European Neuromuscular Center (ENMC) diagnostic criteria for “clinico-pathologically defined sIBM” at the time of biopsy. Among these, 2 patients developed sIBM after years of immunosuppressive treatment for organ transplantation. Of 11 patients fulfilling the histological but not the clinical criteria, including 3 cases with duration <12 months, 8 later fulfilled the criteria for clinico-pathologically defined sIBM. Of 7 PM-Mito patients, 4 received immunosuppression with clinical improvement in 3. One of these later developed clinico-pathologically defined sIBM; 1 untreated patient progressed to clinically defined sIBM. Thus, muscle histology remains important for this differential diagnosis to identify sIBM patients not matching the ENMC criteria and the PM-Mito group. In the latter, we report at least 50% positive, if occasionally transient, response to immunosuppressive treatments and progression to sIBM in a minority. The mitochondrial abnormalities defining PM-Mito do not seem to define the threshold to immunosuppression unresponsiveness.Keywords
This publication has 31 references indexed in Scilit:
- Polymyositis with cytochrome C oxidase negative fibers—a pathological and clinical challengeAnnals of Diagnostic Pathology, 2013
- Long-term observational study of sporadic inclusion body myositisBrain, 2011
- Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFα and rituximabClinical Rheumatology, 2010
- Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositisBrain, 2009
- Inflammatory myopathies with mitochondrial pathology and protein aggregatesJournal of the Neurological Sciences, 2009
- TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementiaJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBMNeurology, 2008
- Long‐term persistence of clonally expanded T cells in patients with polymyositisAnnals of Neurology, 2004
- Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapyBrain, 1997
- Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathiesAnnals of Neurology, 1991